AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Depreciation & Amortization · Q4 FY2024 · quarter ended Dec 2024
Depreciation & amortization of €85K in Q4 FY2024
Q4 FY2024 depreciation & amortization was €85K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
Currency unavailable · from the cash flow
No Depreciation & Amortization data reported for this period type.
Depreciation & Amortization vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M USD | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $2.43M USD | +1.2% | +1.2% | 1.0% | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
| LTM Mar 2026 | $107K USD | -22.5% | -0.6% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -10.6% | +0.3% | 6.3% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.